Stephen K. Doberstein Sells 1,701 Shares of Nektar Therapeutics (NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 1,701 shares of the stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $19.55, for a total value of $33,254.55. Following the transaction, the senior vice president now owns 32,803 shares of the company’s stock, valued at $641,298.65. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Nektar Therapeutics (NASDAQ:NKTR) traded up 1.74% during midday trading on Monday, hitting $19.28. The company had a trading volume of 890,605 shares. The company’s market cap is $2.99 billion. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The company’s 50 day moving average is $19.20 and its 200-day moving average is $15.48.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The firm had revenue of $24.73 million for the quarter, compared to analyst estimates of $29.43 million. During the same period in the previous year, the business posted ($0.14) EPS. Nektar Therapeutics’s revenue for the quarter was down 58.0% compared to the same quarter last year. On average, equities analysts predict that Nektar Therapeutics will post ($1.19) EPS for the current year.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

WARNING: This article was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://sleekmoney.com/stephen-k-doberstein-sells-1701-shares-of-nektar-therapeutics-nktr-stock/1844533.html.

Several hedge funds have recently made changes to their positions in NKTR. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock valued at $470,234,000 after buying an additional 20,024,448 shares during the last quarter. Camber Capital Management LLC raised its stake in shares of Nektar Therapeutics by 87.5% in the fourth quarter. Camber Capital Management LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock valued at $73,620,000 after buying an additional 2,800,000 shares during the last quarter. Norges Bank purchased a new stake in shares of Nektar Therapeutics during the fourth quarter valued at $31,574,000. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Nektar Therapeutics during the first quarter valued at $23,580,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Nektar Therapeutics during the first quarter valued at $23,580,000. 86.80% of the stock is currently owned by institutional investors.

NKTR has been the subject of several research analyst reports. Aegis increased their target price on Nektar Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, March 20th. Roth Capital set a $31.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research note on Monday, March 20th. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 target price (up from $15.00) on shares of Nektar Therapeutics in a research note on Friday, March 3rd. Zacks Investment Research upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 27th. Finally, JPMorgan Chase & Co. set a $24.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $25.25.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

12 Month Chart for NASDAQ:NKTR

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/stephen-k-doberstein-sells-1701-shares-of-nektar-therapeutics-nktr-stock/1844533.html

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *